NANUET, N.Y.--(BUSINESS WIRE)--Vemics, Inc. (OTCBB: VMCI) today announced that its iMedicor HIPAA compliant medical communications portal will be utilized by a major pharmaceutical company in a specialized marketing program to commence June 1.
This company, which is traded on the New York Stock Exchange, will use iMedicor to distribute customized marketing messages on a pain management product to a targeted list of over 100,000 physician specialists nationwide. These messages will comprise product-specific educational resources and will be transmitted in real time on a 24/7 basis. Doctors receiving these messages may subsequently utilize iMedicor to order product samples, set appointments with pharma sales representatives and communicate directly with pharma medical science liaisons.
In return for use of iMedicor, Vemics will receive a start-up fee plus recurring fees for the transactions listed above.
The iMedicor program is expected to significantly reduce the need for live visits by pharmaceutical sales reps to physicians’ offices, and broaden the scope and quality of communications between pharmaceutical companies and physicians. In addition, iMedicor estimates its system will slash the cost of in-person marketing by as much as 80 percent per encounter and create a higher return on investment for the pharma.
The program’s messages will be created and managed by pharmaceutical marketing firm Franklyn Ideas, which currently serves some of the world’s largest pharmas and which has engineered marketing programs for hundreds of brands.
Vemics chief executive, Fred Zolla, said, “Today’s announcement marks a milestone in our drive to provide pharmaceutical companies with state-of-the art technology delivering targeted marketing messages proven to elicit the highest rate of response among healthcare providers.
“With the pharmaceutical marketing expertise of Franklyn Ideas, we anticipate making this program an unqualified success—and one that could encourage other pharmas to follow suit.”
No comments:
Post a Comment